Home

Metsera, Inc. - Common Stock (MTSR)

52.12
+0.00 (0.00%)
NASDAQ · Last Trade: Oct 2nd, 4:32 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close52.12
Open-
Bid52.00
Ask52.12
Day's RangeN/A - N/A
52 Week Range12.30 - 54.47
Volume316
Market Cap-
PE Ratio (TTM)-4.050
EPS (TTM)-12.9
Dividend & YieldN/A (N/A)
1 Month Average Volume3,401,829

Chart

News & Press Releases

Got $200? 2 Healthcare Stocks to Buy and Hold Foreverfool.com
These stocks could see growth take off over the next few years.
Via The Motley Fool · October 1, 2025
Metsera Reports Up To 14% Weight Loss In Phase 2b Obesity Trialbenzinga.com
Metsera's MET-097i cut weight up to 14% in Phase 2b trials, with manageable side effects, as the company targets a global Phase 3 program in 2025.
Via Benzinga · September 30, 2025
Pfizer Just Reminded Investors Why You Should Never Count Its Stock Outfool.com
The company recently announced an acquisition that will bolster its growth prospects in the GLP-1 obesity market.
Via The Motley Fool · September 30, 2025
Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3
Placebo-subtracted mean weight loss up to 14.1% after 28 weeks with no plateau
By Metsera, Inc. · Via GlobeNewswire · September 29, 2025
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PINC, MTSR, HOUS, ODP on Behalf of Shareholders
NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
By Halper Sadeh LLC · Via GlobeNewswire · September 29, 2025
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Premier, Inc. (Nasdaq – PINC), Metsera, Inc. (Nasdaq – MTSR), Anywhere Real Estate Inc. (NYSE – HOUS), The ODP Corporation (Nasdaq – ODP)
BALA CYNWYD, Pa., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
By Brodsky & Smith LLC · Via GlobeNewswire · September 29, 2025
3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Incomefool.com
Right now, these dividend payers are top options for folks who like to set it and forget it.
Via The Motley Fool · September 29, 2025
Down 55%, Should You Buy the Dip on Pfizer?fool.com
Pfizer is facing a patent cliff and has a high payout ratio, but it is taking steps to get back on track.
Via The Motley Fool · September 28, 2025
Is Pfizer Stock a Buy After Its $5 Billion GLP-1 Bet?fool.com
The company continues to improve its pipeline.
Via The Motley Fool · September 27, 2025
Pfizer is Locking in New Growth Through a New Acquisitionmarketbeat.com
Pfizer is undergoing a new acquisition, exposing it to the weight loss market and additional revenue growth potential, which isn't priced in yet.
Via MarketBeat · September 26, 2025
Did Pfizer Just Give Investors 7 Billion Reasons to Buy Its Stock?fool.com
The pharmaceutical giant is again plunging headfirst into weight-loss drug development.
Via The Motley Fool · September 26, 2025
2 Top Passive Income Stocks to Buy Nowfool.com
These dividend stocks offer high yields and growth catalysts that could support payouts for decades.
Via The Motley Fool · September 26, 2025
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARIS, MTSR, GTLS, MURA on Behalf of Shareholders
NEW YORK, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
By Halper Sadeh LLC · Via GlobeNewswire · September 23, 2025
METSERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale Metsera, Inc. (NasdaqGS: MTSR) to Pfizer Inc. (NYSE: PFE). Under the terms of the proposed transaction, shareholders of Metsera will receive $47.50 per share in cash at closing, plus a non-transferable contingent value right entitling holders to potential additional payments of up to $22.50 per share in cash tied to three specific clinical and regulatory milestones. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
By Kahn Swick & Foti, LLC · Via Business Wire · September 23, 2025
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARIS, MTSR, ODP, SMLR on Behalf of Shareholders
NEW YORK, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
By Halper Sadeh LLC · Via GlobeNewswire · September 23, 2025
What's Pfizer Getting in Its $7.3 Billion Metsera Buyout?fool.com
Pfizer's plan to enter the booming obesity market took an expensive new turn.
Via The Motley Fool · September 23, 2025
Viking Therapeutics Stock Gets Boost From Pfizer-Metsera Deal, Says BTIG — Retail Slams Rivals For Buying ‘Inferior Pipelines’stocktwits.com
BTIG said Pfizer’s $7.3 billion Metsera acquisition sharpens its clinical updates and strategic optionality.
Via Stocktwits · September 22, 2025
Top stock movements in today's session.chartmill.com
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · September 22, 2025
Why Pfizer Stock Just Poppedfool.com
Pfizer's own GLP-1 drug candidate failed earlier this year -- so it's buying someone else's.
Via The Motley Fool · September 22, 2025
Nvidia, Metsera, Oracle, Apple, Compass: Stocks Making The Biggest Moves Todaystocktwits.com
Via Stocktwits · September 22, 2025
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Premier, Inc. (Nasdaq – PINC), Metsera, Inc. (Nasdaq – MTSR), Anywhere Real Estate Inc. (NYSE – HOUS), The ODP Corporation (Nasdaq – ODP)
BALA CYNWYD, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
By Brodsky & Smith LLC · Via GlobeNewswire · September 22, 2025
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga.com
Via Benzinga · September 22, 2025
Top movers analysis in the middle of the day on 2025-09-22: top gainers and losers in today's session.chartmill.com
Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · September 22, 2025
Gold Gains Over 1%; Quantum Computing Shares Plungebenzinga.com
Via Benzinga · September 22, 2025
Let's uncover which stocks are experiencing notable gaps during today's session.chartmill.com
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · September 22, 2025